US business pain to continue until capacity constraints are sorted US business for Q2FY17 declined 54.8% YoY at Rs3,220 mn, this decline was mainly attributable gAbilify whose exclusivity got over and severe competition in gNexium. Company plans to launch 4-7 products in FY17. We remain cautious on its launch as currently TRP has 3 approvals but have not launched the product; gDetrol LA further sales are also impacted by capacity constraints. The...